Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.82 EUR
−21.71 M EUR
0.00 EUR
43.75 M
About Context Therapeutics Inc.
Sector
CEO
Martin A. Lehr
Headquarters
Philadelphia
Website
Founded
2015
FIGI
BBG013TG0HC4
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 6K9 is 0.82 EUR — it has increased by 0.62% in the past 24 hours. Watch CONTEXT THERAPEUTICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange CONTEXT THERAPEUTICS INC stocks are traded under the ticker 6K9.
6K9 stock has risen by 10.96% compared to the previous week, the month change is a 2.53% rise, over the last year CONTEXT THERAPEUTICS INC has showed a −24.54% decrease.
We've gathered analysts' opinions on CONTEXT THERAPEUTICS INC future price: according to them, 6K9 price has a max estimate of 9.59 EUR and a min estimate of 3.84 EUR. Watch 6K9 chart and read a more detailed CONTEXT THERAPEUTICS INC stock forecast: see what analysts think of CONTEXT THERAPEUTICS INC and suggest that you do with its stocks.
6K9 stock is 7.95% volatile and has beta coefficient of 0.39. Track CONTEXT THERAPEUTICS INC stock price on the chart and check out the list of the most volatile stocks — is CONTEXT THERAPEUTICS INC there?
Today CONTEXT THERAPEUTICS INC has the market capitalization of 58.43 M, it has decreased by −17.87% over the last week.
Yes, you can track CONTEXT THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
CONTEXT THERAPEUTICS INC is going to release the next earnings report on Mar 19, 2025. Keep track of upcoming events with our Earnings Calendar.
6K9 earnings for the last quarter are −0.20 EUR per share, whereas the estimation was −0.08 EUR resulting in a −144.44% surprise. The estimated earnings for the next quarter are −0.09 EUR per share. See more details about CONTEXT THERAPEUTICS INC earnings.
CONTEXT THERAPEUTICS INC revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
6K9 net income for the last quarter is −15.68 M EUR, while the quarter before that showed −2.10 M EUR of net income which accounts for −645.03% change. Track more CONTEXT THERAPEUTICS INC financial stats to get the full picture.
No, 6K9 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 28, 2025, the company has 5.00 employees. See our rating of the largest employees — is CONTEXT THERAPEUTICS INC on this list?
Like other stocks, 6K9 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CONTEXT THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CONTEXT THERAPEUTICS INC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CONTEXT THERAPEUTICS INC stock shows the sell signal. See more of CONTEXT THERAPEUTICS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.